FINHUB Insights

WST · Q3 FY25 · Jul 1 – Sep 30, 2025

West Pharmaceutical Services Q3 FY25: where the revenue came from and where it went

West Pharmaceutical Services Q3 FY25: revenue $0.8B (+8% year over year). Net profit $0.1B. Largest cohort Proprietary Products $0.6B. The whole income statement as a sankey diagram from the SEC filing.

Period
Jul 1 – Sep 30, 2025
Reported
Oct 23, 2025 10-Q
Sankey diagram of West Pharmaceutical Services's income statement for Q3 FY25: revenue of $0.8 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$0.8B +8% year over year
Gross profit$0.3B 37% margin
Operating profit$0.2B 21% margin
Net profit$0.1B 17% margin

The numbers

All figures in billions of U.S. dollars, for Q3 FY25 (period ends Sep 30, 2025).
ItemValueShare of revenueYear over year
Revenue 0.8 100% +8%
Proprietary Products 0.6 75% +8%
Contract Manufactured Products 0.2 25% +8%
Cost of revenue−0.562%
Gross profit0.337% margin+1pp
Research & development−02%+0pp
SG&A−0.113%+2pp
Other−01%+0pp
Operating profit0.221% margin−1pp
Net profit0.117%−1pp
Filing on EDGAR More quarters of WST

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters